New inhaled asthma drug shows promise in early trial

NCT ID NCT05276570

Completed Symptom relief Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an inhaled medication called ARO-RAGE in 127 healthy volunteers and people with asthma. The goal was to check safety and how the drug affects lung function. Participants received one or two doses of the drug or a placebo. Results will help decide if larger studies are warranted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Research Site 1

Nedlands, Washington, 6009, Australia
Research Site 1

Auckland, 1010, New Zealand
Research Site 1

Barcelona, 08017, Spain
Research Site 1

Bangkok Noi, Bangkok, 10700, Thailand
Research Site 2

Auckland, 1051, New Zealand
Research Site 2

Krakow, 31-455, Poland
Research Site 3

Auckland, 622, New Zealand
Research Site 3

Oświęcim, 32-600, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.